IBD
TechnologyValuation Breakdown
Technology companies combine high growth potential with the risk of overvaluation. This model blends DCF (60% weight, capturing long-duration growth) with a P/E sanity check (40% weight, capping speculative excess). The DCF uses the slowest growth decay (0.05) recognizing that tech companies can sustain competitive advantages longer. The P/E component applies a dynamic ceiling: max P/E = min(growth% x 1.5, 30), preventing runaway valuations.
Valuation Track Record
Retroactive intrinsic value vs actual close price — IBD
Earnings Quality
Fiscal year 2024
Financial Forensics
Beneish M-Score · 2024
The Beneish M-Score of -1.9892 indicates a potential risk of earnings manipulation, as it is below the threshold of -1.78. Coupled with a low Earnings Quality Score of 34.2, particularly concerning metrics like receivables and revenue, this stock raises significant red flags regarding financial integrity.
- Beneish M-Score of -1.9892 indicates potential earnings manipulation.
- Earnings Quality Score of 34.2/100 suggests poor earnings quality, especially with eq_receivables at 21.9/100 and eq_revenue at 0.0/100.
- DSRI of 1.1414 indicates a slight increase in receivables relative to sales, which can be a positive sign if managed properly.
- SGI of 0.9698 indicates stable sales growth, which may reflect a resilient market position.
The top shareholders include a significant institutional stake of 29.0%, which can provide stability; however, the high concentration of individual ownership (38.6% combined) raises concerns about governance and potential conflicts of interest.
Investors should conduct further due diligence, particularly on cash flow and revenue recognition practices, and consider monitoring for any changes in ownership structure or governance practices.
Generated by AI based on quantitative data. Not financial advice.
Quantitative Scores
Key Ratios
Company Overview
// OWNERSHIP_NETWORK
> mapping common ownership for IBD — hover nodes for intel, click to navigate